Article
Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Oncotarget - 17 Jan 2017
Song Qiaoling, Sun Xiaoxiao, Guo Hui, Yu Qiang
Abstract excerpt
Receptor tyrosine kinase (RTK) signaling pathways are frequently activated in cancer cells due to mutations of RTKs and/or their downstream signaling proteins such as KRAS and BRAF. About 40% colorectal cancers (CRCs) contain KRAS or BRAF mutant genes and are resistant to treatments with individual inhibitors of RTKs, AKT, MEK, or BRAF. Therefore, an understanding of the molecular mechanisms of the drug...
Topics
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Colorectal Neoplasms
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- Drug Synergism
- Female
- HCT116 Cells
- Humans
- Male